|
Envelope surface glycoprotein gp120
|
env
|
HIV-1 gp120 upregulates the expression of IL-6 and IL-8 via the p38 signaling pathway and the PI3K/Akt signaling pathway in astrocytes |
PubMed
|
|
env
|
HIV-1 gp120 activates AKT, ERK1/2, and p38 signaling in tonsil CD4+ T cells. Soluble CD4 inhibits AKT and ERK1/2 activation, but enhances phosphorylation of p38 |
PubMed
|
|
env
|
Gp120-mediated activation of caspase-3 is significantly reduced in cells pretreated with PDGF-B. PDGF-mediated protection against gp120 involves the phosphoinositide (PI)3-kinase/Akt pathway |
PubMed
|
|
env
|
Insulin-like growth factor-I (IGF-I) and erythropoietin treatment protect against HIV/gp120-mediated neuronal damage in culture and in vivo, in part, through cooperative activation of phosphatidylinositol 3-kinase/Akt/GSK-3beta signaling |
PubMed
|
|
env
|
HIV-1 gp120 induced cell death is inhibited by a CCR5-mediated neuroprotective pathway that involves protein kinase Akt/PKB as an essential component and can be triggered by the CCR5 agonists MIP-1beta and RANTES |
PubMed
|
|
env
|
CD45 modulates HIV-1 gp120-induced apoptosis by regulating Fas ligand induction and activation of the phosphoinositide 3-kinase/Akt pathway |
PubMed
|
|
env
|
Fractalkine (CX3CL1) protects hippocampal neurons from the neurotoxicity induced by the HIV-1 envelope protein gp120, and neuronal CX(3)CR1 receptors and Akt activation are responsible for the neuroprotective effects of fractalkine |
PubMed
|
|
env
|
Pre-treatment of endothelial cells with fibroblast growth factor 2 (FGF2) protects cells from HIV-1 gp120 angiotoxicity; this protection is regulated by crosstalk among the ERK, PI3K-AKT and PKC signaling pathways |
PubMed
|
|
env
|
HIV-1 gp120 downregulates expression of c-Myc, Max, and 14-3-3epsilon proteins, and decreases phosphorylation of ATP-dependent tyrosine kinases (Akt) at Ser-473 in human mesangial cells (HMC) |
PubMed
|
|
Nef
|
nef
|
HIV-1 Nef synergizes with KSHV oncoprotein K1 to activate PI3K/AKT/mTOR signaling pathway, and induces cell proliferation and microtubule formation in endothelial cells |
PubMed
|
|
nef
|
Knockdown of AKT2 and AKT3 by siRNA shows significant reduction of CCL5 levels, suggesting that AKT2 and AKT3 proteins are involved in Nef-mediated upregulation of CCL5 |
PubMed
|
|
nef
|
HIV-1 Nef induces phosphorylation of MEK1 at position serine 298, which depends on Pak and Rac activity |
PubMed
|
|
nef
|
HIV-1 Nef synergizes with IL-6 to activate the AKT pathway promoting angiogenesis and tumorigenesis in a chicken chorioallantoic membrane model and nude mice |
PubMed
|
|
nef
|
HIV-1 Nef synergizes with IL-6 to enhance vascular tube formation, cell proliferation, VEGF expression, and phosphorylated AKT activation in human umbilical vein endothelial cells |
PubMed
|
|
nef
|
Incubation of human macrophages with exogenous HIV-1 Nef protein induces phosphorylation of Akt and GSK-3ss, and promotes IL-10 release |
PubMed
|
|
nef
|
HIV-1 Nef decreases levels of AKT phosphorylation in insulin-stimulated adipocytes |
PubMed
|
|
Tat
|
tat
|
HIV-1 Tat-mediated upregulation of CCL5 involves JAK2/3, AKT2/3, p38delta, NF-kappaB (p65/p50), C/EBP alpha/gamma, and AP-1 proteins |
PubMed
|
|
tat
|
Treatment with HIV-Tat and morphine activates extracellular signal-regulated kinase-1/2 (ERK1/2), upregulates p53 and p21 levels, and downregulates cyclin D1 and Akt levels in human fetal brain-derived neural precursor cells |
PubMed
|
|
tat
|
HIV-1 Tat induces phosphorylation of PI3K, AKT, PTEN, and GSK-3beta activating PI3K and AKT and inactivating PTEN and GSK-3beta in vIL-6 expressing cells |
PubMed
|
|
tat
|
PI3K/Akt, TRPC, and GSK3beta signaling pathways are all involved in PDGF-C mediated neuroprotection against HIV-1 Tat in human neuroblastoma cells |
PubMed
|
|
tat
|
HIV-1 Tat activates AKT kinase through activation of PI3 kinase, resulting in the protection of cells from apoptosis |
PubMed
|
|
tat
|
Lancemaside A1 inhibits the movement of Akt to the plasma membrane, a critical step for Akt activation, and Compound K inhibits Akt phosphorylation in Tat-expressing CHME5 cells |
PubMed
|
|
tat
|
PDGF-BB-mediated protection against HIV-1 Tat and morphine-induced neuron apoptosis involves Akt activation |
PubMed
|
|
tat
|
HIV-1 Tat inhibits autophagy in bystander macrophages/monocytic cells through Tat-mediated activation and phosphorylation of Src-Akt signaling |
PubMed
|
|
tat
|
Phosphatidylinositol 3-kinase/Akt signaling pathway is involved in HIV-1 Tat-induced NADPH oxidase stimulation and LTR transactivation |
PubMed
|
|
tat
|
A Coumarin derivative BPRHIV001 modulates Tat function through a reduction of the p300 protein level and a concordant reduction of phosphorylated Akt |
PubMed
|
|
tat
|
Pro-survival effects of intracellular HIV-1 Tat in a microglial cell line is attributed to activation of the PI-3-kinase (PI3K)/Akt pathway via decreasing expression of PTEN, a negative regulator of the PI-3-K pathway |
PubMed
|
|
tat
|
HIV-1 Tat downregulates CREB transcription factor expression in PC12 neuronal cells through activation of a phosphatidylinositol 3-kinase/AKT/cyclic nucleoside phosphodiesterase pathway |
PubMed
|
|
Vpr
|
vpr
|
HIV-1 Vpr-induced upregulation of CCL5 requires p50 and p65 subunits of NF-kappaB, p38delta MAPK, Akt-2 and Akt-3, and AP-1 transcription factor in HIV-1 Vpr transfected astrocytes |
PubMed
|
|
vpr
|
HIV-1 Vpr inhibits Akt-induced cytoplasmic translocation of Foxo3a, a subtype of the forkhead transcription factors |
PubMed
|
|
matrix
|
gag
|
HIV-1 p17 and its C-terminal truncated form of p17 (p17delta36) differentially regulate Akt phosphorylation by reducing and increasing phosphorylation levels of PTEN, respectively |
PubMed
|
|
gag
|
HIV-1 p17 induces capillary-like structures in human endothelial cells by binding to CXCR1 and CXCR2, which requires activation of the Akt-dependent ERK signaling pathway |
PubMed
|